$PFLT

PennantPark Floating Rate Capital Ltd. Announces Financial Results for the Third Quarter Ended June 30, 2026

PennantPark Floating Rate Capital Ltd. (PFLA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 PennantPark Floating Rate Capital Ltd. Announces Financial Results for the Third Quarter Ended June 30, 2026 MIAMI, Aug. 10, 2026 (GLOBE NEWSWIRE) -- PennantPark Floating Rate Capital Ltd. (NYSE: PFLT) announced today its financial results for the third quarter ended

Original reporting
Published Aug 10, 2026, 8:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 11, 2026, 8:09 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$PFLT
Neutral
medium confidence
Mentioned
$PFLT
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$PFLTNeutralMed
01

Why it matters

Traders can use the reported NAV per share, net investment income, distribution declarations, yield, non-accrual counts, and unrealized depreciation to reassess near-term earnings power and credit risk.

02

Market read

Fresh quarterly financial and portfolio metrics are disclosed, including NAV per share at $10.26, NII of $25.9 million, and non-accrual exposure of 1.0% by cost basis.

03

What to watch

The filing emphasizes variable-rate debt (about 99%) and weighted average debt yield (9.8%), so the market may focus on how quickly income and NAV respond to rate changes rather than headline NII alone.

Relevance 7/10Novelty 6/10Timing: after-hours filing Aug. 10, 2026, ahead of Aug. 11 conference call

Background

This is an SEC Form 8-K with Exhibit 99.1 covering PennantPark Floating Rate Capital Ltd.’s Q3 2026 results and portfolio/investment activity for the quarter ended June 30, 2026.

Company-level read

Ticker impact

$PFLTNeutralMedium confidence
Context

PennantPark Floating Rate Capital reported Q3 ended June 30, 2026 results, including net investment income of $25.9 million and NAV per share of $10.26.

Expected impact

Likely modest near-term volatility around the earnings release and any follow-on investor interpretation of NAV, NII, and credit performance.

Evidence & confidence

The filing includes concrete datapoints (NAV per share, NII, yield, non-accruals, unrealized depreciation) but no explicit guidance or capital action beyond the reported quarter.

Market effects

BDC and floating-rate credit investors may reprice risk based on reported variable-rate exposure, non-accrual levels, and unrealized depreciation.

Limited direct regional impact; primarily US credit/BDC sentiment.

Low; credit performance and funding costs are mostly US-focused for this issuer.

Counterpoint

Despite low non-accrual percentages, the portfolio shows net unrealized depreciation of $122.8 million, which could temper optimism if investors focus on mark-to-market pressure.

Key entities

  • PennantPark Floating Rate Capital Ltd.

    BDC-style lender reporting Q3 2026 results, NAV per share, NII, and portfolio credit metrics in an 8-K.

  • Art Penn

    Chairman and CEO quoted on portfolio performance and sector exposure.

Related articles

$PFLTMedAI 9/10

PennantPark Floating Rate Capital Ltd. Prices Public Offering of $100 Million 7.375% Notes due 2031

PennantPark Floating Rate Capital Ltd. (NYSE: PFLT) priced a $100 million underwritten public offering of 7.375% notes due 2031, maturing June 15, 2031. The notes may be redeemed starting June 15, 2028 at 100% plus accrued interest. Expected close is about June 1, 2026; an underwriters’ option allows up to $15 million more. Net proceeds will repay its revolving credit facility, fund investments, and support general corporate purposes.

$SOPHMed

Sophia Genetics SA (SOPH) (Q3 2026) Earnings Call Highlights: Revenue Surges 25% with Strong

Sophia Genetics SA (SOPH) reported a 25% revenue surge in Q3 2026. CEO Ross Muken expects continued growth in 2027, driven by strong product momentum and a high backlog of customers. The company is investing in medical affairs to drive adoption and has secured notable biopharma collaborations, including with AstraZeneca. CFO George Cardoza emphasized profitability commitments and conservative guidance.

$ONHighAI 8/10

Onsemi delays auto restocking as AI sales jump 175%

Onsemi (ON) reported Q3 revenue of $1.72B, up 11% YoY, with AI data center revenue jumping 175% to $180M. The company is prioritizing AI and industrial chip supply, delaying some automotive restocking orders. Onsemi acquired Ferric for $600M to expand AI power management, raising its 2030 AI revenue target to over $3B. Shares rose 4.78% post-earnings.

$MTCHMed

Match Group: 3 Key Takeaways for Long-Term Investors

Match Group expects to exceed its full-year revenue and Adjusted EBITDA margin targets, according to CFO Steve Bailey. The company generated $832 million in free cash flow year-to-date, returning capital to shareholders through buybacks and dividends. Match plans to maintain this strategy in 2027, balancing investments with shareholder returns.

$AEHRHighAI 9/10

Aehr Test Systems (AEHR) (Q1 2027) Earnings Call Highlights: Record Revenue, Raised

Aehr Test Systems (AEHR) reported record Q1 2027 revenue of $33M and raised annual guidance to $150M. CEO Gayn Erickson highlighted a potential large burn-in opportunity, estimating $35M-$70M in revenue per million units shipped. The company expects sequential growth in remaining quarters, with Q4 potentially the highest. Management confirmed they are not supply-constrained and can ship more than guided. Silicon carbide revenue was about $10M in fiscal 2026, with expectations for growth in 2027.

$HLFMedAI 8/10

Herbalife Ltd (HLF) (Q3 2026) Earnings Call Highlights: Fifth Straight Quarter

Herbalife (HLF) reported Q3 2026 net sales of $1.4B, up 6% YoY, and adjusted EBITDA of $182M, beating guidance. Growth was driven by India and nutrition clubs, while EMEA and China saw declines. The company raised full-year sales guidance but expects gradual margin expansion. Interim CEO John DeSimone discussed product repositioning and new technology platforms. Operating cash flow rose 27% YoY, and net leverage improved to 2.0x.